Manhattan BioSolutions secures non-dilutive angel funding

by Mbio2018|Published May 1, 2018

Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University

Published August 26, 2020

EVQLV and Manhattan BioSolutions Enter into Strategic Collaboration to Discover Novel Antibody-Based Therapies

New York, NY August 25, 2020—EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a strategic research collaboration with […]

Published August 23, 2021

EVQLV and Manhattan BioSolutions Announce Grant Award from UB CAT

New York City, New York Jun 29, 2021 (Issuewire.com) – EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, […]

Published March 2, 2021

Manhattan BioSolutions Announces Positive Preclinical Data Validating its Novel Synthetic Microbial Therapeutic Platform

New York City, New York Feb 23, 2021 (Issuewire.com) – Manhattan BioSolutions, Inc, an emerging biotechnology company focused on the discovery of immunoregulatory therapies […]

Back to post list
Next post Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University